Solid Biosciences Inc. (NasdaqGS: SLDB)
Health Care · Biotechnology · US
$6.71
-2.33% today · +14.3% 1Y
Solid Biosciences Inc. (NasdaqGS: SLDB) operates in the Biotechnology industry within the Health Care sector. The company is valued at $736.64M and employs 121 people.
Over the last twelve months the share price has gained 14.3%, trading between 3.79 and 11.45.
Tweenvest scores Solid Biosciences Inc. across four factors: quality 36/100, value 77/100. Its strongest factor is value.
SLDB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $736.64M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.87
- Dividend yield
- —
- Beta (5Y)
- 2.47
- 52-week high
- $11.45
- 52-week low
- $3.79
- Avg volume (3M)
- —
- Shares outstanding
- 107.23M
- Employees
- 121
- Next earnings
- —
About Solid Biosciences Inc.
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.
- ISIN
- US83422E2046
- Founded
- 2013
- Listed since
- Jan 26, 2018
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Verastem, Inc.NasdaqCM: VSTM | $747.15M | $8.25 | -1.55% |
| Gyre Therapeutics, Inc.NasdaqCM: GYRE | $746.48M | $6.87 | -2.49% |
| JS Link, Inc.KOSDAQ: A127120 | $743.20M | ₩28,750.00 | -1.54% |
| HanchorBio Inc.TWSE: 7827 | $739.81M | NT$169.00 | +1.20% |
| 4D Molecular Therapeutics, Inc.NasdaqGS: FDMT | $718.17M | $13.00 | -2.48% |
| ChemPartner PharmaTech Co.,Ltd.SZSE: 300149 | $713.97M | CN¥9.47 | -4.34% |
| Avalo Therapeutics, Inc.NasdaqCM: AVTX | $710.06M | $13.24 | -3.00% |
| MiMedx Group, Inc.NasdaqCM: MDXG | $704.02M | $4.83 | +3.43% |
Figures last refreshed Oct 11, 2026.